Anti-VEGF use for ROP is expanding beyond bevacizumab and ranibizumab, with aflibercept’s fusion-protein structure conferring ...
Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to ...
Analysts covering EyePoint have refreshed their models, with bullish price targets now clustered in the US$29 to US$35 range. These revisions are being linked to more detailed valuation work on the ...
Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results